282539-54-2

Basic information

• Product Name: (2S,3S,5S)-5-[N-tert-butyloxycarbonylamino]-2-[N-[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-7-methyl-1-phenyloctane
• CAS NO: 282539-54-2
• Molecular Weight: 512.69
• Mol File: 282539-54-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (2S,3S,5S)-5-[N-tert-butyloxycarbonylamino]-2-[N-[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-7-methyl-1-phenyloctane(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S,5S)-5-[N-tert-butyloxycarbonylamino]-2-[N-[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-7-methyl-1-phenyloctane(282539-54-2)
• EPA Substance Registry System: (2S,3S,5S)-5-[N-tert-butyloxycarbonylamino]-2-[N-[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-7-methyl-1-phenyloctane(282539-54-2)

Safety Data

• Hazardous Substances Data: 282539-54-2(Hazardous Substances Data)

Upstream product

• 282539-49-5 ((1S,3S,4S)-4-Dibenzylamino-3-hydroxy-1-isobutyl-5-phenyl-pentyl)-carbamic acid tert-butyl ester 
• 282539-45-1 (2S,3S,5S)-5-amino-2-(dibenzylamino)-3-hydroxy-7-methyl-1-phenyloctane 
• 111138-83-1 N,N-dibenzyl-L-phenylalanine benzyl ester 
• 156732-12-6 (4S)-4-(N,N-dibenzylamino)-3-oxo-5-phenyl-pentanonitrile 
• 63-91-2 L-phenylalanine 
• 13335-71-2 2-(2,6-dimethylphenoxy)acetic acid 
• 282539-51-9 (2S,3S,5S)-2-amino-5-[N-tert-butyloxycarbonylamino]-3-hydroxy-7-methyl-1-phenyloctane 

Downstream Products

• 282539-52-0 N-((1S,2S,4S)-4-Amino-1-benzyl-2-hydroxy-6-methyl-heptyl)-2-(2,6-dimethyl-phenoxy)-acetamide 

Relevant articles and documents

Aspartic protease inhibitors

The present invention provides a compound of formula (I) wherein a, b, c, d, and e, are R7, OR7, SR7, NR7R8, NHCOR7, CO2R7, CN, NO2, NH2, N3, or a halogen. R7and R8are H or alkyl, R1and R2are H or alkyl, and R3is a non-aromatic substituent. Substituent A is OH, NH2, or SH. Substituents B and B1include amide and sulfonamide groups, which can be cyclic, acyclic, or amino acid derivatives. Alternatively, B and R′ together with the nitrogen to which they are bonded, and/or B′ and R2together with the nitrogen to which they are bonded, define a heterocycle. The present invention further provides a pharmaceutical composition that includes a carrier and a therapeutically effective amount of at least one compound of the present invention. The present invention further provides therapeutic methods that include administering a therapeutically effective amount of at least one compound of the present invention